15 results about "Lamotrigine" patented technology

The present disclosure relates to novel lamotrigine salts, co-crystals, and compositions. In some embodiments, the lamotrigine salt is a lamotrigine dicarboxylic acid salt or hydrate or solvate thereof. In some embodiments, the lamotrigine co-crystal is a co-crystal of lamotrigine and a dicarboxylic acid, or a hydrate or solvate thereof. In some embodiments, the compositions comprise lamotrigine or a salt or co-crystal thereof, or a hydrate or solvate thereof. In some embodiments, the composition is in the form of a powder. In some embodiments, the composition is in the form of a liquid. The present disclosure also relates to methods of preparation and use in medical therapy, for example, for the treatment of a subject with epilepsy or bipolar disorder.

The present application relates to the technical field of medicine, in particular to a kind of preparation and application of self-microemulsifying composition containing lamotrigine.The self-microemulsifying composition includes lamotrigine and self-microemulsifying drug delivery system (SMEDDS) carrier;The SMEDDS carrier includes: by lamotrigine, oil phase, emulsifier and co-emulsifier;The self-microemulsifying composition, by mass ratio, lamotrigine is 0.1% to 18.7%, oil phase is 20% to 33%, milk phase is 67% to 80%, the milk phase is by emulsifier and co-emulsifier, and the mass ratio of emulsifier and co-emulsifier is 25.7 to 32.9%:67.1% to 74.3%, and the mass concentration of lamotrigine reaches 18.7%.The particle size of microemulsion formed by the self-microemulsifying composition dispersed in aqueous medium is less than 50nm or even smaller.The self-microemulsifying composition is prepared into soft capsule, hard capsule, tablet, granule, temperature-sensitive gel and other dosage forms, and is applied in the preparation of antiepileptic drugs.

Disclosed are ready to use non-aqueous solutions of lamotrigine. The lamotrigine is dissolved in a solvent, wherein the solvent comprises propylene glycol and optionally at least one co-solvent, and wherein if water is present in the ready to use non-aqueous solution, the water is not at least one co-solvent. Also disclosed are methods for treating a neurological disorder or a mental disorder by administering the ready to use non-aqueous solutions of lamotrigine, processes for preparing ready to use non-aqueous solutions of lamotrigine, and kits containing lamotrigine to prepare ready to use non-aqueous solutions of lamotrigine.

The invention discloses a pharmaceutical salt of lamotrigine, a pharmaceutical composition, a preparation method and application. Through a medicine-medicine combination strategy, lamotrigine and lipoic acid are combined in a salifying or mixture form, in epilepsy treatment, lamotrigine fragments can inhibit abnormal discharge and nerve over-excitation in the brain, and lipoic acid fragments can enhance the resistance of the brain to epileptic seizure, so that the epilepsy treatment effect is improved, and the epilepsy treatment effect is improved. The damage to the brain after the epileptic seizure is relieved, a multi-channel treatment effect with a synergistic effect is exerted, and the disease development is delayed. Meanwhile, the formed salt also has better physical and chemical stability, dissolution, pharmacokinetics and pharmacodynamic properties, is more beneficial to medicine formation on the whole, and provides an effective medicine for treating epilepsy.

The invention discloses a lamotrigine oral suspension and a preparation method thereof, the lamotrigine oral suspension is composed of lamotrigine and other pharmaceutic adjuvants, the pharmaceutic adjuvants are composed of a suspending aid, a wetting agent, a bacteriostatic agent, a flavoring agent, a defoaming agent, a pH regulator and a solvent, and the wetting agent is hydroxypropyl methylcellulose, glycerin, Tween 80 and the like. According to the invention, the suspending aid is adopted to increase the liquid viscosity and improve the stability of the suspension, and the wetting agent is adopted to improve the hydrophobicity of API, so that the stability and redispersibility of the suspension are improved, and the preparation process is simple and suitable for industrial mass production.

This application relates to the field of analytical detection technology, specifically to sample pretreatment methods, kits, and detection methods for the detection of antiepileptic drugs. The sample pretreatment method for the detection of antiepileptic drugs in this application includes one or more of the following antiepileptic drugs: valproic acid, carbamazepine, phenytoin, levetiracetam, lamotrigine, and phenobarbital. The sample pretreatment method includes the following steps: mixing magnetic beads with an activation solution to prepare a magnetic bead suspension; mixing the sample to be tested, the magnetic bead suspension, and an internal standard solution, and separating the supernatant and the magnetic bead complex after magnetic adsorption treatment; adding an eluent to the magnetic bead complex, and collecting the magnetic bead-target complex after elution treatment; adding an elution buffer to the magnetic bead-target complex, and collecting the supernatant after elution treatment for detection. The above sample pretreatment method is simple to operate, time-saving, and low-cost, providing key technical support for the efficient quantitative detection of antiepileptic drugs.

The present invention relates to a crystalline form of a lamotrigine hydrate, a method for preparing the same and a composition comprising the same, and in particular, to a lamotrigine hydrate form A, a method for preparing the lamotrigine hydrate form A and a composition comprising the lamotrigine hydrate form A.

The invention relates to the technical field of analysis and detection, in particular to a sample pretreatment method for anti-epileptic drug detection, a kit and a detection method. According to the sample pretreatment method for anti-epileptic drug detection, an anti-epileptic drug comprises one or more of valproic acid, carbamazepine, phenytoin, levetiracetam, lamotrigine and phenobarbital; the sample pretreatment method comprises the following steps: mixing magnetic beads with an activating solution to prepare a magnetic bead suspension; mixing a to-be-detected sample, the magnetic bead suspension and the internal standard solution, performing magnetic attraction treatment, and separating supernate and a magnetic bead compound; leacheate is added into the magnetic bead compound, and after leaching treatment, a magnetic bead-target compound is collected; and adding an eluent into the magnetic bead-target compound, carrying out elution treatment, and collecting a supernatant for detection. The sample pretreatment method is simple to operate, short in time consumption and low in cost, and can provide key technical support for efficient quantitative detection of the anti-epileptic drugs.

The present disclosure relates to novel lamotrigine salts, co-crystals, and compositions. In some embodiments, the lamotrigine salt is a lamotrigine dicarboxylic acid salt or hydrate or solvate thereof. In some embodiments, the lamotrigine co-crystal is a co-crystal of lamotrigine and a dicarboxylic acid, or a hydrate or solvate thereof. In some embodiments, the compositions comprise lamotrigine or a salt or co-crystal thereof, or a hydrate or solvate thereof. In some embodiments, the composition is in the form of a powder. In some embodiments, the composition is in the form of a liquid. The present disclosure also relates to methods of preparation and use in medical therapy, for example, for the treatment of a subject with epilepsy or bipolar disorder.

The application discloses a pharmaceutical salt of lamotrigine, a pharmaceutical composition, a preparation method and application. Through a drug-drug combination strategy, lamotrigine and thioctic acid are combined in the form of a salt or a mixture. In the treatment of epilepsy, the lamotrigine fragment can inhibit abnormal discharge and excessive excitement of the brain, and the thioctic acid fragment can enhance the resistance of the brain to seizures, reduce the damage to the brain after seizures, and play a synergistic multi-pathway treatment effect to delay the development of the disease. Meanwhile, the formed salt has better physical and chemical stability, dissolution, pharmacokinetics and pharmacodynamics, and is more beneficial to the preparation of a medicine, and an effective epilepsy treatment drug is provided.

The present disclosure relates to novel lamotrigine salts, co-crystals, and compositions. In some embodiments, the lamotrigine salt is a lamotrigine dicarboxylic acid salt or hydrate or solvate thereof. In some embodiments, the lamotrigine co-crystal is a co-crystal of lamotrigine and a dicarboxylic acid, or a hydrate or solvate thereof. In some embodiments, the compositions comprise lamotrigine or a salt or co-crystal thereof, or a hydrate or solvate thereof. In some embodiments, the composition is in the form of a powder. In some embodiments, the composition is in the form of a liquid. The present disclosure also relates to methods of preparation and use in medical therapy, for example, for the treatment of a subject with epilepsy or bipolar disorder.

The present disclosure provides a dry pharmaceutical composition, including a therapeutically effective amount of one or more lamotrigine hydrate crystals and one or more pharmaceutically acceptable excipients. The excipients include a thickener. The dry pharmaceutical composition is preferably a dry suspending agent. The dry pharmaceutical composition can be formulated into a suspension available for administration, which is stable for use for at least 1-3 months. The present disclosure further discloses methods for preparing the dry pharmaceutical composition and the dry suspending agent and use of the dry pharmaceutical composition and the dry suspending agent in the treatment of a neurological disease.

The present invention relates to an oral liquid suspension that includes lamotrigine and methods of medical treatment that include administering the oral liquid suspension. The oral liquid suspension has desirable physicochemical properties and technical attributes. The oral liquid suspension is useful in patients having difficulties in swallowing tablets and provide medical practitioners with additional options for dose titration.

The present disclosure provides a pharmaceutical composition for preventing, alleviating or treating neurodegenerative diseases. The present invention relates to a composition comprising a therapeutically effective amount of lamotrigine and rivastigmine, the molar ratio of rivastigmine to lamotrigine being in the range of from 1: 1 to 1: 50. The composition can be prepared into an oral administration form and can be used for treating neurodegenerative diseases such as Parkinson's disease, dementia with Lewy bodies, multi-system atrophy and Alzheimer's disease. The present disclosure also provides a method of treating neurodegenerative disease using the composition, as well as a kit comprising separate dosage forms of lamotrigine and rivastatin and instructions for administration of the lamotrigine and rivastatin.

The present invention relates to an oral liquid suspension that includes lamotrigine and methods of medical treatment that include administering the oral liquid suspension. The oral liquid suspension has desirable physicochemical properties and technical attributes. The oral liquid suspension is useful in patients having difficulties in swallowing tablets and provide medical practitioners with additional options for dose titration.